Novartis AG
Antibody drug conjugates for ablating hematopoietic stem cells
Last updated:
Abstract:
The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
Status:
Grant
Type:
Utility
Filling date:
19 Dec 2017
Issue date:
14 Jun 2022